	iGb3					DMSO				
LPS (min)	0	15	30	60	90	0	15	30	60	90
p-ERK		-	2	-	-	ana e		-	-	-
	0.03	0.62	1.40	1.35	0.93	0.03	0.65	1.27	1.31 (0.85
p-JNK		<u>anaranan</u> Tagadinan		"Nedagaint"		4	MANORA 4		nganadhantainte ⁿ 1	νιατουστατά ν
	0.01	0.14	0.32	0.20	0.15	0.01	0.17	0.32	0.19	0.10
p-p38		_	-	-	-	•	-	-		-
	0.01	0.58	0.57	0.41	0.35	0.01	0.52	0.55	0.36 (0.29
p-IKKα/β			-		-	a again		-		-
	0.01	0.29	0.76	0.77	0.83	0.01	0.16	0.44	0.35 (0.39
ρ-ΙκΒα	•	-	-	-	-		-		-	cutoretuige.
	0.01	0.39	0.25	0.53	0.48	0.01	0.22	0.09	0.28	0.10
p-p65		-	-		-					
	0.08	0.57	0.70	0.64 (J.61	0.01	0.26	0.22	0.24	0.25
p-TBK1	0.04		-	-	-	0.04	0.04	0.50	0.00	
n-IRE3	0.01	0.34	0.82	0.49	0.42	0.01	0.21	0.52	0.26	0.22
p-11(1-0	0.01	0.01	0.01	0.48	0.46	0.01	0.01	0.01	0.28	0.29
β-actin	-					-			-	-



0.13		0.01 0.14 0.3
	р-р38	
0.40		0.01 0.58 0.5
-	p-IKKα/β	-
0.52		0.01 0.29 0.7
-	ρ-ΙκΒα	· ·
0.57		0.01 0.39 0.
	p-p65	Section Control of
3 0.57		0.08 0.57 0.7
	p-TBK1	
3 0.44		0.01 0.34 0.8
	p-IRE3	0.04.0.04.0
0.68	0 actin	0.01 0.01 0.
-	p-actin	
Ч	icha DMSO	е
u -		•
	a while a while	,
	Ne. 60, 06 Ne. 60, 06	
p-ERK	== ==	
	0.01 0.37 0.34 0.01 0.38 0.36	
p-JNK		
	0.01 0.29 0.32 0.01 0.29 0.33	
p-p38		
	0.01 0.50 0.54 0.01 0.45 0.51	1
n-IKKa/B		-
p-ir (r (a/p	0.01 0.41 0.49 0.01 0.27 0.27	
n-lrBa		
p-ikbu	0.01 0.44 0.51 0.01 0.25 0.22	
p-p65		
	0.01 0.47 0.49 0.01 0.32 0.25	
p-TBK1		
P	0.01 0.25 0.23 0.01 0.15 0.11	
B-actin		
p doin		
	iGb3 DMSO	

С

β-actin		
	iGb3	DMSO
	S. W. G	in a will G
	We boy Co	We boy Cb
p-IRF3		
	0.01 0.49 0.35 (0.01 0.31 0.22
β-actin		

	Cd1d ^{_/_}				Cd1d+/+					
LPS(min)) 0	15	30	60	90	0	15	30	60	90
p-ERK	Normality I Provide	-	=	=	=	nananister (nananan	-	=	=	=
	0.02	0.67	1.22	0.99	0.79	0.02	0.63	1.18	0.94	0.80
p-JNK			-						agebore.	
	0.01	0.13	0.41	0.13	0.12	0.01	0.12	0.43	0.11	0.13
p-p38		-	-	-	-		-	-	-	
	0.01	0.59	0.50	0.46	6 0.40	0.01	0.59	0.54	0.47	0.40
p-IKKα/β		-	-	Series/	anter .	•	aataa 🖣		-	
	0.01	0.20	0.45	5 0.36	6 0.29	0.01	0.32	0.92	0.82	0.52
ρ-ΙκΒα		(3500)(Sp			-		-	-manife 1	-	
	0.01	0.15	0.12	2 0.3	6 0.25	0.01	0.32	0.21	0.61	0.57
p-p65		W ithout	-	-	e canna	•		-	-	
	0.01	0.28	0.37	0.3	0 0.21	0.01	0.49	0.99	0.98	0.57
p-TBK1		-	-	~						
	0.01	0.21	0.32	0.3	4 0.24	0.01	0.56	0.74	0.83	0.44
p-IRF3				-	-				-	
	0.01	0.03	0.05	0.2	3 0.31	0.01	0.08	0.10	0.52	0.68
β-actin	-	-	-	-	-	-	-	-	-	-

	Cd1d ^{-/-} Cd1d ^{+/+}
	Wed POHICO Wed POHICO
p-ERK	
n- INK	0.03 0.50 0.52 0.02 0.48 0.56
PONIC	0.01 0.25 0.24 0.01 0.23 0.26
p-p38	
n-IKKa/B	0.02 0.69 0.70 0.01 0.68 0.70
p-intro.p	0.02 0.25 0.41 0.01 0.66 0.75
ρ-ΙκΒα	
p-p65	
	0.01 0.43 0.41 0.01 0.87 0.89
р-ТВК1	0.01 0.29 0.14 0.01 0.57 0.34
β-actin	
	Cd1d ^{-/-} Cd1d ^{+/+}
	Wed POHICO Wed POHICO
p-IRF3	
β-actin	0.01 0.26 0.13 0.01 0.54 0.36

а

b

Supplementary information, Fig. S7 CD1d reverse signaling promotes the activation of TLR signaling in macrophages. a Immunoblot analysis of phosphorylated (p-) signaling molecules in lysates of $Cd1d^{+/+}$ and $Cd1d^{-/-}$ macrophages stimulated with LPS for the indicated times. b Immunoblot analysis of phosphorylated (p-) ERK, JNK, p38, IKKa/β, IkBa, p65 and TBK1 in lysates of $Cd1d^{+/+}$ and $Cd1d^{-/-}$ macrophages stimulated with Poly(I:C) or CpG ODN for 30 min, or phosphorylated IRF3 in lysates of $Cd1d^{+/+}$ and $Cd1d^{-/-}$ macrophages stimulated with Poly(I:C) or CpG ODN for 60 min. c Immunoblot analysis of phosphorylated signaling molecules in lysates of macrophages pretreated with iGb3 and then stimulated with LPS for the indicated times. d Immunoblot analysis of phosphorylated (p-) ERK, JNK, p38, IKK α/β , I κ B α , p65 and TBK1 in lysates of macrophages pretreated with iGb3 and then stimulated with Poly(I:C) or CpG ODN for 30 min, or phosphorylated IRF3 in lysates of macrophages pretreated with iGb3 and then stimulated with Poly(I:C) or CpG ODN for 60 min. e Immunoblot analysis of phosphorylated (p-) ERK, JNK, p38 and p65 in lysates of macrophages stimulated with iGb3 for the indicated times. Data are representative of three independent experiments.